Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials.

Moeber M Mahzari Muhannad Qirnas Alqirnas Moustafa S AlhamadhFaisal AlrasheedAbdulrahman Yousef AlhabeebWedad Al MadaniHussain Aldera

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2024)

Patients suffering from both T2DM and CKD exhibited a significantly enhanced glycemic control when treated with DPP-4 inhibitors in comparison to the control group. Furthermore, no significant difference in the incidence of adverse events was observed between the DPP-4 inhibitors and the control group.

Keyphrases

glycemic control
type diabetes
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
peritoneal dialysis
blood glucose
risk factors
weight loss
clinical trial
metabolic syndrome
patient reported outcomes
adipose tissue
patient reported